Tonix publishes Phase 1 data for TNX-1500; shows TDAR blockade, favorable safety

Tonix Pharmaceuticals Holding Corp.

TNX-1500 Phase 1 data in Journal of Clinical Immunology; blocked primary TDAR at all doses (3,10,30 mg/kg).
Secondary TDAR blocked at 10 and 30 mg/kg; peak secondary reduced ~70% vs placebo at 3 mg/kg.
No serious adverse events; mild aphthous ulcers in 3 participants; half-life supports monthly IV dosing.
Phase 2 investigator-initiated kidney transplant study at MGH expected to start 2H 2026 pending FDA IND clearance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.